HRPC – malecare.org

Cyclophosphamide (Cytoxan®) -Another Possible 2nd Line Chemotherapy for HRPC After Docetaxil Failure

Researchers, Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. from the Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX. studied the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in men who have docetaxel-resistant hormone-refractory prostate cancer (HRPC). […]

Salvage Therapy with High Dose Bicalutamide (Casodex) In Non-metastatic Castration-Resistant Prostate Cancer – It Controls PSA and Disease Progression

Researchers at the Department of Urology, Centre Hospitalier Universitaire du Québec (CHUQ), Quebec, Canada evaluated the rate and duration of prostate-specific antigen (PSA) response to high-dose bicalutamide (150 mg) in men with non-metastatic castration-resistant prostate cancer (nmHRPC) as well as its impact on the duration of metastasis-free survival. They concluded that high dose bicalutamide is [...]